# Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

> **NCT05687266** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 1350 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Datopotamab deruxtecan
- **DRUG:** Durvalumab
- **DRUG:** Carboplatin
- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05687266
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-29
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 1350 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05687266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05687266, "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05687266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*